Business Context and Reporting Period
This Form 8-K was filed by Vistagen Therapeutics, Inc. on September 6, 2022. The Company is incorporated in Nevada and its common stock trades on the Nasdaq Capital Market under the symbol VTGN.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a regulatory compliance issue regarding the Company's stock price.
Material Changes
On September 6, 2022, the Company received a notice from Nasdaq indicating non-compliance with Listing Rule 5550(a)(2). The Company's common stock closing bid price has been below the required minimum of $1.00 per share for the last 30 consecutive business days.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has 180 days (from September 6, 2022, to March 6, 2023) to regain compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days.
- Extension Criteria: If compliance is not met by March 6, 2023, Nasdaq may grant a second 180-day period. Qualification requires meeting the market value of publicly held shares requirement and all other initial listing standards, excluding the minimum bid price.
- Reverse Stock Split: To qualify for an extension, the Company must notify Nasdaq of its intent to cure the deficiency, potentially through a reverse stock split.
- Delisting Risk: Failure to regain compliance within the allotted periods may result in delisting. The Company would be entitled to appeal such a determination to a Nasdaq hearings panel.
- Uncertainty: There is no assurance the Company will regain compliance or maintain other listing requirements.
Investor Verification Checklist
- Verify the current closing bid price of VTGN common stock relative to the $1.00 threshold.
- Monitor the Company's stock price for 10 consecutive business days to determine if compliance is achieved.
- Check for future announcements regarding a potential reverse stock split or intent to cure the deficiency.
- Review the Company's market value of publicly held shares to assess eligibility for a second compliance period if needed.